ArticleESMO open2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.
Article in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.Cancer metastasis reviews · 2026Pooled it
- Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy.Frontiers in oncology · 2025Pooled it
- External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinations.International urology and nephrology · 2026Article
- Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.The oncologist · 2026Article
- Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based Combinations.Cancer reports (Hoboken, N.J.) · 2026Article
- Metastatic Tumour Burden as Prognostic Factor in Nivolumab-Treated Metastatic Renal Cell Carcinoma: An Exploratory Study.Current oncology (Toronto, Ont.) · 2026Article
- Assessment of Meet-URO and CANLPH Prognostic Models in Metastatic RCC: Insights from a Single-Institution Cohort Predominantly Treated with TKIs.Diagnostics (Basel, Switzerland) · 2026Article
- Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.Therapeutic advances in medical oncology · 2026Article
- Real-World Predictors of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: The Emerging Role of the Urologist in Immuno-Oncology.Research and reports in urology · 2026Article
- Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study.Frontiers in oncology · 2026Article
- Prognostic Impact of Metastatic Pattern in Renal Cell Carcinoma: IMDC, IMDC-7, and Meet-URO Scores.Journal of kidney cancer and VHL · 2026Article
- Beyond IMDC: do expanded models improve survival discrimination in metastatic renal cell carcinoma? A real-world cohort study.Frontiers in oncology · 2026Article
- Evaluation of the Meet-URO Score in a Real-World Cohort of mRCC Patients Treated with First-Line TKIs.Journal of clinical medicine · 2025Article
- The Effectiveness and Safety Profile of Nivolumab-Plus-Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J-ENCORE Study).International journal of urology : official journal of the Japanese Urological Association · 2025Observational
- Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Prognostic value of the neutrophil‑to‑lymphocyte ratio in renal cell carcinoma: A systematic review and meta‑analysis.Oncology letters · 2025Article
- Prognostic value of IMDC score in non-small cell lung cancer receiving immunotherapy: old dog, new tricks? : IMDC in lung cancer immunotherapy.European journal of clinical pharmacology · 2025Article
- Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab-a polish multicenter, observational study.Clinical and experimental medicine · 2025Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 20 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Meet-URO score allowed a more accurate prognostication than the International Metastatic RCC Database Consortium (IMDC) for patients with pre-treated metastatic renal cell carcinoma (mRCC) by adding the pre-treatment neutrophil-to-lymphocyte ratio and presence of bone metastases. MATERIALS AND
methodsA post hoc analysis was carried out to validate the Meet-URO score on the overall survival (OS) of patients with IMDC intermediate-poor-risk mRCC treated with first-line nivolumab plus ipilimumab within the prospective Italian Expanded Access Programme (EAP). We additionally considered progression-free survival (PFS) and disease response rates. Harrell's c-index was calculated to compare the accuracy of survival prediction.
resultsOverall the EAP included 306 patients, with a median follow-up of 12.2 months, median OS was not reached, 1-year OS was 66.8% and median PFS was 7.9 months. By univariable analysis, both the IMDC score and the two additional variables of the Meet-URO score were associated with either OS or PFS (P < 0.001 for all comparisons). The four Meet-URO risk groups (G) had 1-year OS of 92%, 72%, 50% and 21% for G2 (29.1% of patients), G3 (28.8%), G4 (33.0%) and G5 (9.1%), respectively. OS was significantly shorter in each consecutive G (P = 0.001 for G3, P < 0.001 for both G4 and G5 compared to G2). Similarly, Meet-URO Gs 2-5 showed decreasing median PFS and response rates. The Meet-URO score showed the highest c-index for both OS (0.73) and PFS (0.67). Limitations include the post hoc nature of this analysis and the lack of a comparative arm to assess predictive value.
conclusionThe Meet-URO score appeared to show better prognostic classification than the IMDC alone in patients with mRCC at IMDC intermediate-poor risk treated with first-line nivolumab and ipilimumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.